NEW YORK, April 19 (GenomeWeb News) - Zeptosens of Witterswil, Switzerland announced today that it has signed an agreement with Beverly, Mass.-based Cell Signaling Technology for the use of CST's reagents in Zeptosens' ZeptoMARK protein array platform.

 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.